Galimedix.com

Galimedix.com has Server used 54.208.101.55 IP Address with Hostname in United States. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2018-03-04 (2 years, 329 days) and hosted in Ashburn United States, server ping response time 115 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Galimedix keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Galimedix
2 Galimedix stock
3 Galimedix therapeutics

Hosting Provider

Website: Galimedix.com
Hostname: ec2-54-208-101-55.compute-1.amazonaws.com
Country:
Region: VA
City: Ashburn
Postal Code: 20147
Latitude: 39.018001556396
Longitude: -77.539001464844
Area Code: 703
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain


New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   » Maofang.org (0 seconds ago)

   » Webbsinc.net (8 seconds ago)

   » Greatwallva.com (5 seconds ago)

   » Test-builder.com (2 seconds ago)

   » Logosquiz-answers.com (29 seconds ago)

   » Hfgxrc.com (15 seconds ago)

   » Galimedix.com (0 seconds ago)

   » Amari.com (17 seconds ago)

   » Edelsteine.net (7 seconds ago)

   » Energizingtheheartland.net (2 seconds ago)

Results For Websites Listing

Found 53 Websites with content related to this domain, It is result after search with search engine

Galimedix Therapeutics, Inc.

(5 day ago) Galimedix Therapeutics is a Phase 2 neuropharmaceutical company developing novel first-in-class drugs with ground-breaking potential to slow or stop the progression of neurodegeneration and to improve function in glaucoma and dry AMD – leading causes of blindness – and also in Alzheimer’s disease.

http://www.galimedix.com/

DA: 17 PA: 17 MOZ Rank: 18

Galimedix Therapeutics, Inc. To Present at Ophthalmology

(7 month ago) About Galimedix Therapeutics, Inc. Based in the United States and Israel, Galimedix is a Phase 2-ready ophthalmic pharmaceutical company with a world class drug development team advancing a novel

https://www.globenewswire.com/news-release/2019/10/08/1926592/0/en/Galimedix-Therapeutics-Inc-To-Present-at-Ophthalmology-Innovation-Summit-During-the-American-Academy-of-Ophthalmology-Meeting.html

DA: 21 PA: 50 MOZ Rank: 50

Galimedix Therapeutics | Start-Up Nation Finder

(7 month ago) Galimedix Therapeutics is a phase-2 clinical-stage ophthalmic pharmaceutical company developing treatments based on a novel mechanism of action directed at the common cause of several neurodegenerative diseases: toxic oligomers of amyloid beta.

https://finder.startupnationcentral.org/company_page/galimedix-therapeutics

DA: 31 PA: 36 MOZ Rank: 67

Galimedix Therapeutics Company Profile: Valuation

(1 month ago) Galimedix Therapeutics General Information Description. Operator of an ophthalmic pharmaceutical company intended to develop novel and transformative treatments directed to the common cause of many neurodegenerative diseases. The company's services include developing a novel treatment that delivers its patented small molecule drug with a unique

https://pitchbook.com/profiles/company/267594-94

DA: 13 PA: 27 MOZ Rank: 40

Galimedix Therapeutics aims to stop the progression of

(4 day ago) Galimedix Therapeutics Inc CEO Dr. Andrew Pearlman sat down with Proactive Investors at the BIO CEO & Investor Conference in New York. The Phase 2 biopharma

https://www.youtube.com/watch?v=9_viHdrKi_c

DA: 15 PA: 6 MOZ Rank: 21

Galimedix, Inc. Appoints Renowned Industry Veteran and

(8 month ago) Galimedix has exclusive worldwide license from Tel Aviv University, following return of license by a German pharma (Merz) due to management change and strategic pivot away from neuroscience. In

https://www.globenewswire.com/news-release/2019/05/06/1817298/0/en/Galimedix-Inc-Appoints-Renowned-Industry-Veteran-and-Innovator-in-the-Field-of-Ophthalmology-Thomas-Hohman-Ph-D-to-Board-of-Directors.html

DA: 21 PA: 50 MOZ Rank: 50

Study Demonstrates Galimedix Therapeutics’ MRZ-99030 Eye

(12 day ago) Galimedix Therapeutics announced the results of a new study at the Society for Neuroscience conference demonstrating that a single application of the investigational compound MRZ-99030, also known as GAL-101, causes sustained prevention of misfolded amyloid beta molecules from aggregating into toxic forms in vitro, neutralizing their ability to be toxic to neural tissues.

https://eyewire.news/articles/new-in-vitro-study-demonstrates-galimedix-therapeutics-investigational-compound-mrz-99030-eye-drops-neutralizes-the-reproduction-of-misfolded-amyloid-beta/

DA: 12 PA: 50 MOZ Rank: 50

Investegate |Galimedix Therapeutics, Inc. Announcements

(6 month ago) About Galimedix Therapeutics, Inc. Based in the United States and Israel, Galimedix is a Phase 2/3-ready ophthalmic pharmaceutical company with a world-class drug development team advancing a novel, patented small molecule drug with a unique MOA addressing glaucoma and dry AMD. The company’s most advanced compound, GAL-101, which utilizes an

https://www.investegate.co.uk/galimedix-therapeutics--inc-/gnw/galimedix-therapeutics--inc--appoints-recognized-industry-veteran--alexander-gebauer--m-d---ph-d---as-executive-chairman/20191021133005H3809/

DA: 21 PA: 50 MOZ Rank: 50

Galimedix on Vimeo

(2 month ago) This is "Galimedix" by Vision Futures Ltd on Vimeo, the home for high quality videos and the people who love them.

https://vimeo.com/358763305

DA: 9 PA: 10 MOZ Rank: 19

Recently Analyzed Sites

Maofang.org (1 seconds ago)

Webbsinc.net (9 seconds ago)

Greatwallva.com (6 seconds ago)

Test-builder.com (3 seconds ago)

Logosquiz-answers.com (30 seconds ago)

Hfgxrc.com (16 seconds ago)

Galimedix.com (1 seconds ago)

Amari.com (18 seconds ago)

Edelsteine.net (8 seconds ago)